This technology, offered for licensing, provides a novel and potentially non-toxic approach to treat a wide range of cancers using RNA Inhibitors.
These biocompatible, non-toxic nanospheres are 20-80 nm in size and due to their hydrophilc-hydrophobic nature, are ideally suited for encapsulating drugs.
This peptide-based drug candidate has a broad range of antimicrobial activity and specific capabilities to fight Pseudomonas aeruginosa. Safe with low toxicity. Can envision this to be an effective anti-sepsis drug.